Background. Bacille Calmette-Guérin (BCG), an attenuated strain of Mycobacterium bovis, is widely used as adjunctive therapy for superficial bladder cancer. Intravesical administration of BCG has been associated with systemic infection. Disseminated infection due to M. bovis is otherwise uncommon.
Bacille Calmette-Guérin (BCG), an attenuated strain, was derived from multiple passages of a wild-type Mycobacterium bovis isolate from cattle almost a century ago [1] . Since then, the BCG vaccine has been used for the control of tuberculosis (TB) spread worldwide, notably in neonates in high prevalence countries [2] . Intravesical administration of BCG has become a cornerstone of adjunctive therapy for superficial bladder cancer [3] . Immunostimulation by BCG effectively eradicates existing carcinoma in situ and decreases the probability of tumor recurrence or progression [4] .
Disseminated infection due to M. bovis-BCG has emerged in 2 clinical scenarios. A few cases of disseminated BCG disease resulting from vaccination have been described in immunocompromised infants or in older children coinfected with human immunodeficiency virus [5, 6] . Intravesical administration of BCG has been related with systemic infectious complications in immunocompetent and immunocompromised hosts [7, 8] . In most cases tissue invasion and hematogenous spread of BCG appear to underlie this complication, rather than an immune-mediated hypersensitivity reaction [7] . Outside these 2 settings, the occurrence of iatrogenic infection by BCG has been described in a few case reports of patients with hematologic malignancies [9] [10] [11] [12] . These authors suggested that the route of infection was the accidental inoculation of M. bovis BCG during the preparation and administration of cancer chemotherapy.
In the present study, we report 9 cases of healthcare-associated BCG infection (HCBCGI) in patients who had not received prior intravesical BCG instillation. All patients developed a systemic BCG infection through the apparent colonization of an implantable central venous catheter (CVC) and subsequent pulmonary mycobacterial disease either alone or with extrapulmonary dissemination by M. bovis-BCG. We also report the epidemiologic study of this cluster of patients with a prior history of maintenance of their CVC at 4 different outpatient oncology clinics where BCG was used to treat patients with bladder cancer.
METHODS

Study Development
In September 2013, a patient was diagnosed with pulmonary infection due to BCG at the Hospital de Barcelona, Spain. The specific route of acquisition of the infection remained unclear. In 2015, 2 other patients at the same hospital were diagnosed with systemic infection caused by BCG in a 1-month period. None of them had received either intravesical BCG or BCG vaccination. As a result, the clinical features and risk factors of these 3 patients, detected in a short period of time, were examined.
The 3 patients had all previously received chemotherapy for a nonbladder cancer and they all had a CVC with an implantable port (Port-a-Cath). The maintenance and heparization of their CVC was performed in an outpatient setting where other patients received intravesical BCG instillations. We contacted the Public Health Agency of Barcelona to study this cluster of 3 similar cases and to determine the mechanism of BCG infection and to identify or prevent other possible cases.
Detection of Other Cases and Investigation of Source of Infection
TB is a reportable disease in Spain and suspected TB cases must be reported to regional or local public health authorities. TB programs of Barcelona and Catalonia have registries of cases to be able to follow up each case until the end of treatment.
The registers of the TB programs of Barcelona and Catalonia from 1 January 2005 to 31 December 2015 were consulted searching for infections caused by M. bovis-BCG. Patients with BCG disease who had not received intravesical BCG instillation were included in the study. Those patients who had received previous BCG therapy were excluded.
For each patient included who had a CVC, we identified the outpatient clinic where CVC maintenance was performed. A complete epidemiological study of all clinics was conducted, including the operating procedures in BCG management.
"Risk patient visits" were considered visits in which the CVC maintenance was performed within 15 days of an intravesical BCG instillation in the same room at a given center. This period selected was the maximum time between the cleaning of surfaces in the room (made with bleach or alcohol derivates). Incubation times were estimated from each risk exposure to the onset of symptoms.
Microbiological Methods
The strains of M. bovis-BCG isolated from all the included patients were collected from the 4 largest hospitals in Barcelona. These laboratories perform the microbiological study of all samples received from their hospitals or from other associated centers in the city. They routinely save the mycobacterial isolates from clinical cultures.
Lower respiratory tract specimens such as bronchoaspirate, bronchoalveolar lavage, and the CVC tip were cultured in Löwenstein-Jensen tubes and BACTEC MGIT 960 automated continuously monitoring system (Becton Dickinson, New Jersey). M. bovis-BCG strains were identified by polymerase chain reaction (PCR) of the regions of difference [13] .
Mycobacterial Interspersed Repetitive Units-Variable Number Tandem Repeat Genotyping
A mycobacterial interspersed repetitive units-variable number tandem repeat (MIRU-VNTR) genotyping study of all recovered positive samples was carried out at Sant Pau Hospital, Barcelona, to correlate BCG samples with the same BCG (OncoTICE) used as adjunctive therapy for superficial bladder cancer in most outpatient clinics. The BCG-ImmuCyst used in one clinic is no longer commercially available. Therefore, in this case, the correlation was made with the BCG profile previously described [14] .
Genomic DNA was extracted using Instagene Matrix (BioRad Laboratories, California) following the manufacturer's instructions. MIRU-VNTRs were amplified from 24 genomic loci by multiplex PCRs using standardized protocols [15] . The PCR products were separated by capillary electrophoresis on an ABI3500 sequencer with GeneScanTM 1200 LIZ (Applied Biosystems, California) as size standard. Sizing of the PCR fragments and assignments of MIRU-VNTR alleles were performed with GeneMapper software version 4.1 (Applied Biosystems).
Statistical Analysis
A descriptive analysis of the cases was performed. Continuous variables were expressed by means and range. Categorical variables were expressed as percentages. Statistical analyses were conducted using SPSS version 17.0 (IBM SPSS).
Ethical Considerations
TB is a mandatory reportable disease, and the follow-up of patients, contact tracing, and outbreak investigations are requirements for public health professionals. The data used were treated following ethical principles for research involving humans, as defined in the Declaration of Helsinki of 1964 reviewed by the World Health Organization in Fortaleza, Brazil, in 2013. To ensure data confidentiality, all data and records were treated anonymously during the analysis and the patients were followed up at all times within the rules established by the Spanish Personal Data Protection Act of 1999.
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RESULTS
Epidemiology
From 2005 to 2015, 50 people were diagnosed with systemic infections due to M. bovis or M. bovis-BCG and 9 met the study's inclusion criteria. Therefore, 9 patients who had not received intravesical BCG instillation developed BCG disease (Figure 1 ). At the time of diagnosis of HCBCGI, all patients had long-term CVC with subcutaneous reservoir (Port-a-Cath), which was periodically maintained with heparin or saline solutions at 4 different outpatient oncology clinics (5 at clinic A, 2 at clinic B, 1 at clinic C, and 1 at clinic D). Data from clinic D could not be recovered because the practices and staff had changed, unlike the other clinics.
These facilities were oncological offices at which other patients received intravesical BCG instillations for bladder cancer. Therefore, all patients who met the inclusion criteria were oncological patients who had a permanent catheter. There were no cases in noncancer patients or in oncology patients without long-term CVC. None of these 9 patients had direct contact with patients who had received intravesical BCG.
Bacille Calmette-Guérin Management
Operating procedures in BCG management performed in the various oncology clinics are shown in Table 1 .
Clinic A: BCG and the heparin solution (for CVC maintenance) were prepared and administered by the same nurse and in the same place. A multidose heparin solution was used. The adequate dilution of BCG was achieved after several transfers between syringes without using a closed system. Manipulations were performed on the same worktable where the opened heparin was stored. Nurses were not aware that they were manipulating a living organism and they did not follow standard operating procedures for cleaning and disinfection after BCG use.
Clinic B: BCG was prepared in a safety cabinet, but the cabinet was not disinfected after BCG use. A multidose heparin solution was used. BCG preparation and heparin solution might be performed in the same day, by the same nurse and carried in the same tray.
Clinic C: Written protocols were in place for the management of BCG, but the cabinet was not disinfected after BCG use. BCG was carried in the same tray as the heparin solution. Clinic D: There were no data because the practices and staff had changed. BCG is prepared in closed circuits and protocols are followed nowadays.
Incidence of Healthcare-Associated Bacille Calmette-Guérin Infection Among Exposed Patients at Clinic A
Complete data of all patient visits for BCG instillation and for the maintenance of CVC from 1 January 2014 to 31 December 2015 were recorded at clinic A. Two of 9 individuals (patient 1 and 2) who performed CVC maintenance developed HCBCGI (attack rate, 22.2%). These 9 patients accumulated 37 visits for maintenance of their CVC. In the same period, 18 vials of BCG were administered to another patient. Fourteen of 37 visits met the criteria of risk visit. In 1 patient, the only risk visit was made 15 days after the preparation of BCG. The 2 patients who developed HCBCGI had only 1 risk visit each. The incidence of HCBCGI among the risk exposures was 2 of 14 (14.2%)
The other 3 patients (patients 3, 4, and 5), seen between 1 January 2007 and 31 December 2013 at clinic A, accumulated 33 visits, 9 of which were considered risk visits. Full data on the rest of those patients who received CVC maintenance and did not develop BCG-TB were not collected.
Incubation Periods of Healthcare-Associated Bacille Calmette-Guérin Infection Patients
Data of risk visits were available in 7 of 9 patients diagnosed with HCBCGI (Table 1 ). These 7 patients accumulated a total of 61 maintenance visits (patients 1, 2, 3, 4, 5, 6, and 7). Fourteen of these visits met the criteria for risk visit. The possible incubation periods ranged from 47 to 381 days, with a median of 183 days. In the 3 patients with only 1 risk exposure (patients 1, 2, and 6), possible incubation periods were 381, 47, and 57 days, respectively.
Clinical and Microbiological Data
Demographic, clinical characteristics, treatment, and outcomes of the 9 patients with HCBCGI are summarized in Table 2 . The median age of patients was 69 years (range, 47-80 years) and 5 (56%) were female. All had a history of solid tumor cancer and had a permanent CVC. Oncologists preferred patients to keep catheters due to the potential need for future chemotherapy. At the onset of infection, all patients had no evidence of cancer or their cancer was stable. None were receiving chemotherapy or immunosuppressive therapy. The median time from catheter insertion was 3.7 years (range, 1.6-8.8 years). All patients developed pulmonary infection and 2 also developed possible extrapulmonary disease with granulomatous hepatitis. Catheter cultures performed in the last 3 patients supported BCG catheter infection. All patients required admission to 4 different hospitals in Barcelona. Infections were treated with a combination of 3 or 4 drugs. Treatment duration ranged from 9 to 30 months.
Three patients received treatment alone without catheter removal. Treatment outcome was favorable in 8 cases. One patient treated without catheter removal developed a relapse and was cured after catheter removal and re-treatment. Three patients died, after finishing TB treatment, due to causes not related to BCG infection.
Strains were recovered in 8 of 9 culture-positive patients to perform the molecular typing. This study shows that all recovered strains corresponded to the same BGCs used in the 4 outpatient settings to treat the bladder cancer in other patients (Table 3) . In 7 patients, the BCG-OncoTICE was used in 3 settings, and in 1 patient the BCG-ImmuCyst was used in the fourth setting (Tables 1 and 3 ). In parallel with the accumulating evidence of nosocomial BCG transmission, preventive action was taken and all oncology clinics and hospitals in Barcelona were notified to minimize the possibility of new cases. Information on proper management of BCG was provided. Clinic A stopped the performing of BCG instillations. So far, no new cases of healthcare BCG infections have been identified in any clinic.
DISCUSSION
The present study shows the possibility of nosocomial colonization of permanent catheters with BCG and the subsequent systemic infection in patients who have not previously received intravesical BCG. This mechanism of BCG transmission has not been previously described in the literature. This study includes a cluster of 9 cases at 4 different outpatient clinics over a 10-year period. The detection of 4 clinics with the same problem facilitated the identification of the causes. Several deviations from appropriate operating procedures in BCG management explain the cross-contamination and the consequent development of infections due to BCG. The onset of symptoms in some patients occurred a long time after the risk exposure, suggesting a predisposition of BCG to create biofilms after colonizing and infecting intravascular catheters. The ability to survive environmental stresses and biofilm formation has previously been assessed in in vitro biofilm models by M. bovis [16] . However, the presence of catheter infection by M. bovis or BCG in clinical practice has not been described to date.
The viability of M. bovis under different environmental conditions was described in an experimental study [17] . Our study confirms the clinical relevance of BCG viability on environmental surfaces. In agreement with other publications [9] [10] [11] [12] , we suggest that the most plausible route of environmental contamination was via aerosolization during the manipulation of BCG. The accidental flushing of the heparin with the BCG solution is a potential explanation for the cross-contamination. The colonization of the outside of the CVC or the multidose vial of heparin by colonized gloves, due to contamination of surfaces or equipment, is another possibility. We ruled out a pulmonary acquisition by aerosol transmission with secondary hematogenous dissemination due to lack of other cases. There were no cases among cancer patients without CVC in those oncology clinics, and there were no cases among the medical workers.
Although nosocomial infection by BCG has been proposed in some case reports [9] [10] [11] [12] , the route of acquisition remains unclear. The complete epidemiological study and the identification of BCG in these CVC confirm the route of TB infection in our study. In contrast to previous reports, the patients who developed BCG infection did not present with underlying malignancies. Patients either had no evidence of cancer disease or their cancer was stable, and none were receiving chemotherapy at the onset of HCBCGI.
Pulmonary involvement after catheter-related bloodstream infection by BCG in all the patients in the current study is an interesting finding. Even in the absence of a respiratory transmission, mycobacteria may have a predisposition to pulmonary infection. Pulmonary involvement has rarely been described in catheter-related bloodstream infection by rapidly growing mycobacteria [18, 19] . The connection between the indwelling CVC near the right atrium and the lung as the first blood filter may be decisive. In experimental studies, the lung infection has frequently been described in different mouse models, following not just aerosolized TB infection but intravenous TB infection as well [20, 21] .
Other similar cases of nosocomial BCG transmission have not been reported, possibly reflecting a low level of suspicion of this route of BCG transmission. The possibility of BCG infection may be underestimated because some laboratories do not routinely perform the identification of the species within the Mycobacterium tuberculosis complex. Moreover, M. bovis-BCG is not notifiable at the national or European level as an iatrogenic infection. While notification of TB cases to public health authorities is mandatory, outbreaks of TB caused by M. bovis-BCG are extremely difficult to identify.
Our study has some limitations. First, all data were obtained retrospectively. Therefore, the confirmation of BCG growing in CVC was available only in the 3 cases in which catheter culture for mycobacteria was performed. We assumed a catheter-related infection in all cases due to the epidemiologic association and the absence of other plausible sources of infection. Second, our study focused on the city of Barcelona; a wider study might have allowed the identification of additional cases. Third, we did not investigate other oncology sites in which both procedures were performed and cases were not detected to determine the differences in center practices. At our center, the preparation of BCG is made following specified procedures in BCG management and using closed circuits. Separate professionals perform the maintenance of the heparin catheter. So far, we had not had any case of iatrogenic BCG infection. Despite these limitations, our study strongly supports the possibility of iatrogenic catheter-related infection by BCG with the subsequent development of a systemic BCG infection with important clinical implications. The study implies changes in the approach to the evaluation of BCG infection beyond the patient with previous BCG instillation.
The prevention and management of BCG-related infections might include the following recommendations for infection control and patient safety:
• Proper handling of BCG [22, 23] , including preparation in an isolation area by staff wearing protective equipment. BCG must be prepared inside an exclusive laminar flow cabinet or a special T-catheter with a closed circuit so as to avoid aerosols [24] . Complete disinfection of the room or cabinet must be performed after its use.
• A 4-drug regimen should be started when a new mycobacterial case is diagnosed because of the proportion of cases caused by organisms that are resistant to isoniazid [25] . This strategy is also useful when there is the suspicion of BCG disease due to its intrinsic resistance to pyrazinamide. When BCG is confirmed, a standard treatment with a 3-drug regimen (rifampicin, isoniazid, and ethambutol) is appropriate.
• On the basis of recommendations regarding catheter removal in patients with catheter-related bloodstream infection [26] , we would also recommend the withdrawal of the permanent catheter in these patients.
Notes
